12:00 AM
Sep 13, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Kineret anakinra regulatory update

FDA granted Orphan Drug designation for Swedish Orphan Biovitrum's Kineret anakinra to treat cryopyrin-associated periodic syndromes (CAPS). The IL-1 receptor...

Read the full 79 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >